Uncontrolled Status, Disease Burden, and Associated Risk Factors Among Patients with Asthma Receiving Medium-to-High Dose ICS or ICS/LABA: A Retrospective Analysis
Authors:
Open Access
- 21 July 2026
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (10) , 4749-4765
Abstract
No abstract availableKeywords
Funding Information
- Sanofi and Regeneron Pharmaceuticals Inc.
This publication has 39 references indexed in Scilit:
- Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma RegistryAnnals of Allergy, Asthma & Immunology, 2023
- Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness GroupWorld Allergy Organization Journal, 2022
- Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma: An analysis from the Hokkaido Severe Asthma Cohort StudyAllergology International, 2021
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsJournal of Allergy and Clinical Immunology, 2020
- Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in JapanAllergology International, 2020
- Prevalence, risk factors, and management of asthma in China: a national cross-sectional studyThe Lancet, 2019
- Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthmaAllergology International, 2018
- Asthma Over the Age of 65: All's Well That Ends WellThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Oral corticosteroid exposure and adverse effects in asthmatic patientsJournal of Allergy and Clinical Immunology, 2018
- Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposisJournal of Allergy and Clinical Immunology, 2011